The Clinical Characteristics of Different SARS-COV-2 Variants in South Kalimantan

Haryati Haryati, Desi Rahmawaty

Abstract


COVID-19 has numerous variations as a result of ongoing mutations. Presumably, each variant has its particular clinical characteristic. We present three cases of COVID-19 patients, each with a Non-VOC, delta variant, and probable omicron variant with equal severity and few comorbidities for uniform comparison. All three cases had common COVID-19 symptoms. However, anosmia or ageusia was not found in the probable Omicron case, and the onset was shorter. Infiltrates in chest X-rays were found in all three cases. Laboratory examination showed altered inflammatory markers, transaminitis, and electrolyte imbalance. The standard therapy was given to all patients. However, additional therapies, tocilizumab, IVIG, and plasma convalescent, were given only to Non-VOC and delta variants cases. Non-VOC and delta cases were discharged for self-isolation in 11 and 15 days of treatment. Meanwhile, in the probable Omicron variant, the patient was discharged by his will after being treated for eight days.

Keywords


COVID-19; delta; probable omicron; Non-VOC; clinical characteristics

Full Text:

PDF

References


World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2022 [cited 2022 Feb 12]. https://covid19.who.int/

Das JK, Roy S. A study on non-synonymous mutational patterns in structural proteins of SARS-CoV-2. Genome. 2021;1–14. http://dx.doi.org/10.1139/gen-2020-0157

World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. 2022 [cited 2022 Feb 12]. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern

Luo CH, Morris CP, Sachithanandham J, Amadi A, Gaston D, Li M, et al. Infection with the SARS-CoV-2 Delta variant is associated with higher infectious virus loads compared to the Alpha variant in both unvaccinated and vaccinated individuals. bioRxiv. 2021. http://dx.doi.org/10.1101/2021.08.15.21262077

Townsend JP, Hassler HB, Wang Z, Miura S, Singh J, Kumar S, et al. The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study. Lancet Microbe. 2021;2(12):e666–75. http://dx.doi.org/10.1016/s2666-5247(21)00219-6

Fibriani A, Stephanie R, Alfiantie AA, Siregar ALF, Pradani GAP, Yamahoki N, et al. Analysis of SARS-CoV-2 genomes from west java, Indonesia. Viruses. 2021;13(10):2097. http://dx.doi.org/10.3390/v13102097

Kadir A, Deby S, Muhammad A. A Systematic Review of Omicron Outbreak in Indonesia : A Case Record and How Country is Weathering the New Variant of COVID-19. 2022;09(01):364–73.

Khan NA, Al-Thani H, El-Menyar A. The emergence of new SARS-CoV-2 variant (Omicron) and increasing calls for COVID-19 vaccine boosters-The debate continues. Travel Med Infect Dis. 2022;45(102246):102246. http://dx.doi.org/10.1016/j.tmaid.2021.102246

Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020;12(7):6049–57. http://dx.doi.org/10.18632/aging.103000

Alam MR, Kabir MR, Reza S. Comorbidities might be a risk factor for the incidence of COVID-19: Evidence from a web-based survey. Prev Med Rep. 2021;21(101319):101319. http://dx.doi.org/10.1016/j.pmedr.2021.101319

Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531–8. http://dx.doi.org/10.1007/s00392-020-01626-9

Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med. 2020;8(9):853–62. http://dx.doi.org/10.1016/s2213-2600(20)30316-7

Bajaj V, Gadi N, Spihlman AP, Wu SC, Choi CH, Moulton VR. Aging, immunity, and COVID-19: How age influences the host immune response to Coronavirus infections? Front Physiol. 2021;11. http://dx.doi.org/10.3389/fphys.2020.571416

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061. http://dx.doi.org/10.1001/jama.2020.1585

Lei S, Jiang F, Su W, Chen C, Chen J, Mei W, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine. 2020;21(100331):100331. http://dx.doi.org/10.1016/j.eclinm.2020.100331

Pyar KP, Hla SA, Aung SM, Wunn D, Htet Aung ZN, Maung NL, et al. Breakthrough infection among fully vaccinated physicians working in COVID-19 treatment centers; Prevalence, presenting symptoms, co-morbidities and outcome in the third wave of epidemics in Myanmar. J Biomed Res Environ Sci. 2021;2(8):721–30. http://dx.doi.org/10.37871/jbres1303

Mulazim P, Bukhari H. Recently Discovered Omicron : Fifth Wave of Pandemic in Pakistan. What Strategies Can be adopted to Control its Spread ? Vol. 16, JIIMC. 2021 [cited 2022 Feb 17]. p. 212–4. https://journals.riphah.edu.pk/index.php/jiimc/article/view/1164

Armando F, Beythien G, Kaiser F, Allnoch L, Heydemann L, Rosiak M, et al. SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of Syrian golden hamsters (Mesocricetus auratus). 2022 Feb 1; http://dx.doi.org/10.21203/rs.3.rs-1315280/v1

Sohrabi MR, Amin R, Maher A, Bahadorimonfared A, Janbazi S, Hannani K, et al. Sociodemographic determinants and clinical risk factors associated with COVID-19 severity: a cross-sectional analysis of over 200,000 patients in Tehran, Iran. BMC Infect Dis. 2021;21(1). http://dx.doi.org/10.1186/s12879-021-06179-4

Moradi EV, Teimouri A, Rezaee R, Morovatdar N, Foroughian M, Layegh P, et al. Increased age, neutrophil-to-lymphocyte ratio (NLR) and white blood cells count are associated with higher COVID-19 mortality. Am J Emerg Med. 2021;40:11–4. http://dx.doi.org/10.1016/j.ajem.2020.12.003

Gungor B, Atici A, Baycan OF, Alici G, Ozturk F, Tugrul S, et al. Elevated D-dimer levels on admission are associated with severity and increased risk of mortality in COVID-19: A systematic review and meta-analysis. Am J Emerg Med. 2021;39:173–9. http://dx.doi.org/10.1016/j.ajem.2020.09.018

Taj S, kashif A, Arzinda Fatima S, Imran S, Lone A, Ahmed Q. Role of hematological parameters in the stratification of COVID-19 disease severity. Ann Med Surg (Lond). 2021;62:68–72. http://dx.doi.org/10.1016/j.amsu.2020.12.035

Pranata R, Lim MA, Yonas E, Huang I, Nasution SA, Setiati S, et al. Thrombocytopenia as a prognostic marker in COVID-19 patients: diagnostic test accuracy meta-analysis. Epidemiol Infect. 2021;149(e40). http://dx.doi.org/10.1017/s0950268821000236

Anirvan P, Narain S, Hajizadeh N, . Aloor FZ, Singh SP, Satapathy SK. Cytokine-induced liver injury in coronavirus disease-2019 (COVID-19): untangling the knots. Eur J Gastroenterol Hepatol. 2021;33(1S):e42–9. http://dx.doi.org/10.1097/meg.0000000000002034

Vadiraj PK, Thareja S, Raman N, Karantha SC, Jayaraman M, Vardhan V. Does Raised Transaminases Predict Severity and Mortality in Patients with COVID 19? J Clin Exp Hepatol. 2022;12(4):1114–23. http://dx.doi.org/10.1016/j.jceh.2022.01.004

Pourfridoni M, Abbasnia SM, Shafaei F, Razaviyan J, Heidari-Soureshjani R. Fluid and Electrolyte Disturbances in COVID-19 and Their Complications. Cavalcanti Rolla V, editor. Biomed Res Int. 2021;2021:1–5. http://dx.doi.org/10.1155/2021/6667047

PDPI, PERKI, PAPDI, PERDATIN, IDAI. Pedoman Tata Laksana COVID-19. 4th ed. 2022.

Yang R, Yu Y. Glucocorticoids are double-edged sword in the treatment of COVID-19 and cancers. International Journal of Biological Sciences [Internet]. 2021;17(6):1530–7. Available from: http://dx.doi.org/10.7150/ijbs.58695

Rahmawaty D, Nadia Muslimah Annisa, Haryati. Hemostatic Factors and Its Correlation with Outcomes of COVID-19 Confirmed Patients in Ulin Regional Hospital Banjarmasin. ACI (Acta Cardiol Indones). 2021;7(2):7. http://dx.doi.org/10.22146/jaci.v7i2.1241

Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med. 2020;18(1). http://dx.doi.org/10.1186/s12967-020-02339-3

Herth FJF, Sakoulas G, Haddad F. Use of Intravenous Immunoglobulin (Prevagen or Octagam) for the Treatment of COVID-19: Retrospective Case Series. Respiration. 2020;99(12):1145–53. http://dx.doi.org/10.1159/000511376

Huang S, Shen C, Xia C, Huang X, Fu Y, Tian L. A Retrospective Study on the Effects of Convalescent Plasma Therapy in 24 Patients Diagnosed with COVID-19 Pneumonia in February and March 2020 at 2 Centers in Wuhan, China. Med Sci Monit. 2020;27. http://dx.doi.org/10.12659/msm.928755




DOI: https://doi.org/10.18196/mmjkk.v23i2.15009

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

      

Editorial Office:
Journal Room, G1 (Biomedic) Building, Ground Floor, Faculty of Medicine and Health Science Universitas Muhammadiyah Yogyakarta, 
Jalan Lingkar Selatan (Brawijaya), Tamantirto, Kasihan, Bantul, Daerah Istimewa Yogyakarta, Indonesia
Phone: +62 274 387 656 (ext: 231)
WA : +62 811-2650-303
Website: http://journal.umy.ac.id/index.php/mm 
E-mail: mmjkk@umy.university

Creative Commons License
Mutiara Medika: Jurnal Kedokteran dan Kesehatan is licensed under a Creative Commons Attribution 4.0 International License. View My Stats